OBI Pharma’s Board of Directors approves the announcement of the Company’s 2017 individual and consolidated financial statements

The board of directors have resolved 2017 not to distribute dividends
March 9, 2018
Announcement on the Change of Chief Financial Officer
March 9, 2018

1. Date of occurrence of the event: 2018/03/09
2. Company name: OBI Pharma, Inc
3. Relationship to the Company (please enter “head office” or “subsidiaries”):Parent
4. Reciprocal shareholding ratios: N/A
5. Cause of occurrence: The Company’s 2017 individual and consolidated financial statements were approved by the board of directors. Essential financial items are presented below.

From the 2017 Individual Financial Statement
Operating loss                                               :(1,188,216) KNTD
Total comprehensive loss for the period :(1,400,095) KNTD
Loss Per Share (in dollars)                          :(          8.06) NTD

From the 2017 Consolidated Financial Statement
Operating loss                                               :(1,189,642) KNTD
Total comprehensive loss for the period :(1,400,095) KNTD
Loss Per Share (in dollars)                          :(          8.06) NTD

6. Countermeasures: N/A
7. Any other matters that need to be specified: None